May 20, 2013

NASDAQ OMX[®] News release

NASDAQ OMX WELCOMES DIAMYD MEDICAL TO FIRST NORTH

Stockholm, May 20 2013 — NASDAQ OMX (NASDAQ: NDAQ) announces that the trading in Diamyd Medical AB (short name: DMYD B) shares commenced today on First North at NASDAQ OMX Stockholm. Diamyd Medical belongs to the Healthcare sector and is the eighth new company to be admitted to trading on First North in 2013.

Diamyd Medical is a diabetes company headquartered in Stockholm, Sweden. The company develops the diabetes vaccine Diamyd® and the active ingredient GAD for the treatment and prevention of type 1-diabetes. Two researcher-initiated Phase II studies with Diamyd® are ongoing. Diamyd Medical AB (formerly Diamyd Therapeutics AB) was recently spun out from the publicly traded Mertiva AB (formerly Diamyd Medical AB). For more information about Diamyd Medical please visit www.diamyd.com.

"The new company structure is well positioned to continue the work to find a cure for type 1-diabetes," says Peter Zerhouni, CEO of Diamyd Medical. "As a separately listed entity on First North, Diamyd Medical is able to gain a stronger focus on the continued development of our diabetes vaccine while reaching out to a broad investor audience. We will also leverage our expertise and worldwide network in diabetes to assess the potential to expand our business in terms of products in the diabetes area."

"We welcome Diamyd Medical to First North, one of Europe's most liquid growth markets," says Adam Kostyal, Senior Vice President at NASDAQ OMX. "We've experienced a marked inflow of life science companies and Diamyd is our fourth addition to the healthcare sector this year".

Diamyd Medical has appointed Remium Nordic AB as Certified Adviser.

About First North

First North is regulated as a multilateral trading facility, operated by the different exchanges within NASDAQ OMX Nordic. It does not have the legal status as an EU-regulated market. Companies at First North are subject to the rules of First North and not the legal requirements for admission to trading on a regulated market. The risk in such an investment may be higher than on the main market.

About NASDAQ OMX Group

The inventor of the electronic exchange, The NASDAQ OMX Group, Inc., fuels economies and provides transformative technologies for the entire lifecycle of a trade - from risk management to trade to surveillance to clearing. In the U.S. and Europe, we own and operate 26 markets, 3 clearinghouses and 5 central securities depositories supporting equities, options, fixed income, derivatives, commodities, futures and structured products. Able to process more than 1 million messages per second at sub-40 microsecond speeds with 99.99+% uptime, our technology drives more than 70 marketplaces in 50 developed and emerging countries into the future, powering 1 in 10 of the world's securities transactions. Our award-winning data products and

worldwide indexes are the benchmarks in the financial industry. Home to approximately 3,300 listed companies worth more than \$6 trillion in market cap whose innovations shape our world, we give the ideas of tomorrow access to capital today. Welcome to where the world takes a big leap forward, daily. Welcome to the NASDAQ OMX Century. To learn more, visit www.nasdaqomx.com. Follow us on Facebook (www.facebook.com/NASDAQ) and Twitter (www.twitter.com/nasdaqomx). (Symbol: NDAQ and member of S&P 500)

Cautionary Note Regarding Forward-Looking Statements

The matters described herein contain forward-looking statements that are made under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements about futures products to be traded on NFX and NASDAQ OMX's other products and offerings. We caution that these statements are not guarantees of future performance. Actual results may differ materially from those expressed or implied in the forward-looking statements. Forward-looking statements include, but are not limited to factors detailed in NASDAQ OMX's annual report on Form 10-K, and periodic reports filed with the U.S. Securities and Exchange Commission. We undertake no obligation to release any revisions to any forward-looking statements.

MEDIA RELATIONS CONTACT:

- + Carl Norell
- + +46 (0) 8 405 6639
- + Carl.Norell@nasdaqomx.com